Optimal approaches to analyzing functional MRI data in glioma patients.

Background: Resting-state fMRI is increasingly used to study the effects of gliomas on the functional organization of the brain. A variety of preprocessing techniques and functional connectivity analyses are represented in the literature. However, there so far has been no systematic comparison of how alternative methods impact observed results.
New Method: We first surveyed current literature and identified alternative analytical approaches commonly used in the field. Following, we systematically compared alternative approaches to atlas registration, parcellation scheme, and choice of graph-theoretical measure as regards differentiating glioma patients (N = 59) from age-matched reference subjects (N = 163).
Results: Our results suggest that non-linear, as opposed to affine registration, improves structural match to an atlas, as well as measures of functional connectivity. Functionally- as opposed to anatomically-derived parcellation schemes maximized the contrast between glioma patients and reference subjects. We also demonstrate that graph-theoretic measures strongly depend on parcellation granularity, parcellation scheme, and graph density.
Comparison With Existing Methods and Conclusions: Our current work primarily focuses on technical optimization of rs-fMRI analysis in glioma patients and, therefore, is fundamentally different from the bulk of papers discussing glioma-induced functional network changes. We report that the evaluation of glioma-induced alterations in the functional connectome strongly depends on analytical approaches including atlas registration, choice of parcellation scheme, and graph-theoretical measures.
Competing Interests: Declaration of Competing Interest KYP, JSS, PHL, AZS, report the following conflict of interest. Licensing of Intellectual Property: Sora Neuroscience. AS reports the following conflict of interest. Stock ownership: TheraPanacea. DSM reports the following conflict of interest. Stock ownership: Sora Neuroscience, Flywheel Exchange LLC. ECL reports the following conflicts of interest. Stock ownership: Neurolutions, General Sensing, Osteovantage, Pear Therapeutics, Face to Face Biometrics, Immunovalent, Caeli Vascular, Acera, Sora Neuroscience, Inner Cosmos, Kinetrix, NeuroDev. Petal Surgical. Consultant: Monteris Medical, E15, Acera, Alcyone, Intellectual Ventures, Medtronic, Neurolutions, Osteovantage, Pear Therapeutics, Sante Ventures, Microbot. Licensing of Intellectual Property: Neurolutions, Osteovantage, Caeli Vascular, Sora Neuroscience. Washington University owns equity in Neurolutions. The other authors report they have no competing interests.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)